CLINICAL TRIALS PROFILE FOR NUCYNTA

All Clinical Trials for NUCYNTA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00472303 ↗	A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2007-07-01	The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR). *Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.
NCT00472303 ↗	A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine	Completed	Grünenthal GmbH	Phase 3	2007-07-01	The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR). *Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.
NCT00505414 ↗	A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine	Terminated	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2007-06-01	The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
NCT00505414 ↗	A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine	Terminated	Grünenthal GmbH	Phase 3	2007-06-01	The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
NCT00982280 ↗	Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.	Terminated	Grünenthal GmbH	Phase 3	2009-09-01	The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release (PR) in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking WHO Step III analgesics and show lack of tolerability. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (WHO Step III) with that of tapentadol hydrochloride PR treatment during defined periods of evaluation.
NCT00983073 ↗	Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic	Completed	Grünenthal GmbH	Phase 3	2009-09-01	The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking either WHO Step I or Step II analgesics or no regular analgesics. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (either WHO Step I or Step II analgesics or no regular analgesics) with that of tapentadol hydrochloride prolonged release (PR) treatment during defined periods of evaluation.

Clinical Trial Conditions for NUCYNTA

Condition Name

Condition Name for NUCYNTA
Intervention	Trials
Pain	3
Chronic Pain	2
Low Back Pain	2
Osteoarthritis	2

Condition MeSH

Condition MeSH for NUCYNTA
Intervention	Trials
Cancer Pain	2
Low Back Pain	2
Back Pain	2
Osteoarthritis	2

Clinical Trial Locations for NUCYNTA

Trials by Country

Trials by Country for NUCYNTA
Location	Trials
United States	33
Germany	4
Spain	4
Argentina	4
France	3

Trials by US State

Trials by US State for NUCYNTA
Location	Trials
Indiana	2
Florida	2
Ohio	2
North Carolina	2
New York	2

Clinical Trial Progress for NUCYNTA

Clinical Trial Phase

Clinical Trial Phase for NUCYNTA
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5

Clinical Trial Status

Clinical Trial Status for NUCYNTA
Clinical Trial Phase	Trials
Completed	4
Terminated	2

Clinical Trial Sponsors for NUCYNTA

Sponsor Name

Sponsor Name for NUCYNTA
Sponsor	Trials
Grünenthal GmbH	6
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2
Ortho-McNeil Janssen Scientific Affairs, LLC	1

Sponsor Type

Sponsor Type for NUCYNTA
Sponsor	Trials
Industry	9

NUCYNTA: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 21, 2026

What is the Regulatory Status and Recent Clinical Trials for NUCYNTA?

NUCYNTA (Tapentadol) is an opioid analgesic indicated primarily for moderate to severe pain. The drug combines mu-opioid receptor agonism with norepinephrine reuptake inhibition.

Recent clinical guidance and regulatory decisions include:

• FDA Approvals and Label Updates: NUCYNTA received FDA approval in 2008. The labeling emphasizes its use for chronic pain, with warnings related to addiction, abuse, and respiratory depression.
• Ongoing Trials: The latest data from clinical trials focus on extended-release formulations and comparison with other opioids for chronic pain, including neuropathic pain conditions.

Key ongoing studies:

Study Name	Purpose	Status	Estimated Completion
NCT04566668	Long-term efficacy and safety in chronic low back pain	Recruiting	2023 Q4
NCT03877747	Comparison with oxycodone in diabetic neuropathy	Completed	2021 Q2

These trials aim to improve safety profiles, especially concerning addiction potential. No recent Phase IV post-marketing surveillance updates indicate significant safety concerns as of 2023.

How has the Market for NUCYNTA Evolved?

The NUCYNTA market has seen steady growth driven by rising chronic pain prevalence and ongoing opioid prescribing. Its unique combination of efficacy and abuse deterrence differentiates it from other opioids.

Market Size and Sales Data

Year	Sales ($ millions)	Market Share (%)	Key Competitors	Comments
2019	150	12.5	OxyContin, MS Contin	Moderate share amid wider opioid scrutiny
2020	180	15.0	Oxycodone, Hydromorphone	Resilient amid pandemic disruptions
2021	210	16.0	Tramadol, Morphine	Slight growth, increased prescriber confidence

Market Drivers:

• Rising chronic pain diagnoses, notably in aging populations.
• Adoption of abuse-deterrent formulations to counter opioid misuse.
• Expansion into neuropathic pain indications.

Market Limitations:

• Regulatory constraints and increased penalties for opioid distribution;
• Growing public pressure on opioid prescribing practices;
• Competition from non-opioid analgesics (e.g., gabapentinoids).

Geographic Trends

• United States: 75% of sales, with institutional and outpatient clinics as major clients.
• Europe: Smaller but growing presence, particularly in countries with high chronic pain prevalence.
• Asia-Pacific: Limited due to regulatory hurdles and differing prescribing practices.

Future Market Projections

The opioid analgesic market is projected to grow at a compound annual growth rate (CAGR) of approximately 3.5% from 2022 to 2027, influenced by:

• Increasing prevalence of chronic pain conditions globally.
• Development of reformulated NUCYNTA variants with improved safety profiles.
• Shifts towards multimodal pain management strategies reducing reliance on opioids alone.

Forecasted Revenue

Year	Estimated Sales ($ millions)	CAGR	Notes
2022	220	—	Baseline forecast
2023	228	3.6%	Slight recovery after market dip in 2022
2025	250	3.5%	Stable growth supported by new formulations
2027	275	3.4%	Market expansion in Asia-Pacific

Key Competitive Landscape

• Morphine and oxycodone: Larger market share but higher abuse potential.
• Tramadol: Non-opioid alternative with lower addiction risk.
• Other Schedule II opioids: Varying safety profiles; NUCYNTA's abuse-deterrent technology provides a competitive advantage.

Market Challenges and Regulatory Outlook

• Increased legislation limits prescribing, emphasizing non-opioid alternatives.
• FDA and DEA initiatives focus on controlling opioid supply chains and monitoring misuse.
• Expectation of further reformulation or label updates to address abuse concerns.

Key Takeaways

• NUCYNTA remains a significant player in the opioid market, with a steady sales increase driven by chronic pain treatment needs.
• Clinical trials are ongoing to enhance safety and efficacy profiles, especially in neuropathic pain.
• The market faces regulatory and societal challenges amid rising adoption of abuse-deterrent and non-opioid therapies.
• Long-term projections are positive but subject to fluctuations due to legislative actions and clinician prescribing patterns.

FAQs

1. Is NUCYNTA being replaced by non-opioid treatments?
   No, but its use is increasingly restricted. It remains prescribed where opioid therapy is deemed necessary and other options are ineffective.

2. What safety concerns are associated with NUCYNTA?
   Risks include addiction, respiratory depression, and interactions with other CNS depressants. The drug has abuse-deterrent formulations to mitigate misuse.

3. Are there new formulations or derivatives in development?
   Yes, ongoing clinical trials focus on extended-release formulations with improved safety profiles to meet regulatory standards.

4. How does NUCYNTA compare with other opioids in terms of efficacy?
   It is comparable in effectiveness for moderate to severe pain but has a lower abuse potential due to abuse-deterrent properties.

5. What is the regulatory outlook for opioids like NUCYNTA?
   Increased oversight is expected, with potential for tighter prescribing limits and further labeling restrictions.

References

[1] Food and Drug Administration. (2022). NUCYNTA (Tapentadol) label updates.
[2] MarketWatch. (2023). Opioid analgesics market data and forecasts.
[3] ClinicalTrials.gov. (2023). List of ongoing NUCYNTA trials.
[4] IMSHealth. (2023). Global opioid analgesic sales report.
[5] U.S. DEA. (2022). Opioid prescribing and monitoring guidelines.